Searching for an Elusive Phantom - Targeting Estrogen in Pulmonary Hypertension
- PMID: 38924495
- PMCID: PMC11544367
- DOI: 10.1164/rccm.202405-1029ED
Searching for an Elusive Phantom - Targeting Estrogen in Pulmonary Hypertension
Comment on
-
Pulmonary Hypertension and Anastrozole (PHANTOM): A Randomized, Double-Blind, Placebo-Controlled Trial.Am J Respir Crit Care Med. 2024 Nov 1;210(9):1143-1151. doi: 10.1164/rccm.202402-0371OC. Am J Respir Crit Care Med. 2024. PMID: 38747680 Clinical Trial.
References
-
- Shapiro S, Traiger GL, Turner M, McGoon MD, Wason P, Barst RJ. Sex differences in the diagnosis, treatment, and outcome of patients with pulmonary arterial hypertension enrolled in the registry to evaluate early and long-term pulmonary arterial hypertension disease management. Chest . 2012;141:363–373. - PubMed
-
- Novella S, Pérez-Cremades D, Mompeón A, Hermenegildo C. Mechanisms underlying the influence of oestrogen on cardiovascular physiology in women. J Physiol . 2019;597:4873–4886. - PubMed
-
- White K, Johansen AK, Nilsen M, Ciuclan L, Wallace E, Paton L, et al. Activity of the estrogen-metabolizing enzyme cytochrome P450 1B1 influences the development of pulmonary arterial hypertension. Circulation . 2012;126:1087–1098. - PubMed
Publication types
Grants and funding
LinkOut - more resources
Full Text Sources